This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosand, J. Search for Related Content PubMed PubMed Citation Articles by Rosand, J. Related Collections Acute Cerebral Hemorrhage Genetics of Stroke Related Article

(Stroke. 2005;36:1879.)
© 2005 American Heart Association, Inc.

Original Contributions

Editorial Comment—Epistasis Is Coming

Are We Ready?

Jonathan Rosand, MD, MSc

Vascular and Critical Care Neurology, and the Center for Human Genetic Research, Massachusetts General Hospital, Boston, Mass

Key Words: amyloid • angiography • genetics • intracerebral hemorrhage

An extract of the first 250 words of the full text is provided, because this article has no abstract.

For physicians and patients, the central challenge of human genetics is unraveling the genetic architecture of human diseases. Depending on the disease, this architecture can range from simple to complex. In the so-called mendelian diseases, 1 mutation in a single gene is sufficient to cause disease, whereas more complex diseases may involve changes in single genes, multiple genes, or even combinations of alleles within the same gene. The payoff for successful disease-gene discovery is likely to be enormous, leading to novel biologic discoveries and innovative interventions that can alleviate human suffering. The search so far, however, has been slower than we would all like. The nagging problem is that for most common diseases, the culprit gene variants contribute only a small proportion of disease risk. Successful studies must therefore detect relatively weak associations, and finding weak associations requires very large samples of patients.

Epistasis, broadly defined, is the interaction between alleles at different loci, or positions, in the genome. Most simply, a variant at 1 locus can prevent a variant at another locus from manifesting its effect.^1,2 These combinations of variants may be in different genes, or they may be within the same gene, eg, within the regulatory and coding regions. Ultimately, epistatic interaction is synergistic, with an effect that differs from the simple sum of the effects of each individual allele.

The analysis of haplotypes has become a widely used technique in the search for disease genes because it allows investigators to assess the disease contribution of large sections . . . [Full Text of this Article]

Related Article:

Association of Apolipoprotein E4 and Haplotypes of the Apolipoprotein E Gene With Lobar Intracerebral Hemorrhage

Daniel Woo, Ritesh Kaushal, Ranajit Chakraborty, Jessica Woo, Mary Haverbusch, Padmini Sekar, Brett Kissela, Arthur Pancioli, Edward Jauch, Dawn Kleindorfer, Matthew Flaherty, Alexander Schneider, Pooja Khatri, Laura Sauerbeck, Jane Khoury, Ranjan Deka, and Joseph Broderick
Stroke 2005 36: 1874-1879. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				A. Baessler, M. Fischer, B. Mayer, M. Koehler, S. Wiedmann, K. Stark, A. Doering, J. Erdmann, G. Riegger, H. Schunkert, et al. Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease Hum. Mol. Genet., April 15, 2007; 16(8): 887 - 899. [Abstract] [Full Text] [PDF]